The efficacy and safety of chemotherapy in patients with nonsmall cell lung cancer and interstitial lung disease: A PRISMA-compliant Bayesian meta-analysis and systematic review

Medicine (United States)

Volumn 94, Issue 36, 2015, Pages

  Chen, Yu Jie ^a   Chen, Ling Xiao ^a   Han, Mei Xiang ^a   Zhang, Tian Song ^b   Zhou, Zhi Rui ^c   Zhong, Dian Sheng ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Shanghai Jing'an District Central Hospital   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEMATODAL AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COMORBIDITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERSTITIAL LUNG DISEASE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84941655399     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001451     Document Type: Article

References (40)

1. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005;11:431-437.
2. Archontogeorgis K, Steiropoulos P, Tzouvelekis A, et al. Lung cancer and interstitial lung diseases: a systematic review. Pulm Med. 2012;2012:315918.
3. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91(Suppl 2):S3-S10.
4. Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6:1242-1246.
5. Kenmotsu H, Naito T, Mori K, et al. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015;75:521-526.
6. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer (Amsterdam, Netherlands). 2011;71:70-74.
7. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J. 2003;22:821-826.
8. Molina-Molina M, Marin-Arguedas BJ. Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit. A study of 20 cases. Med Clin. 2003;121:63-67.
9. Camps C, Felip E, Garcia-Campelo R, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clin Transl Oncol. 2013;15:977-984.
10. Chang JY, Kestin LL, Barriger RB, et al. ACR Appropriateness Criteria(R) nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology (Williston Park, N Y). 2014;28:706-710712, 714 passim.
11. Viswanathan MAM, Berkman N. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. AHRQ Publication No. 12-EHC047-EF. Rockville, MD: Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. Available at: www.effectivehealthcare. ahrq.gov; 2012.
12. Lunn DJ, Best N, Thomas A, et al. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn. 2002;29:271-307.
13. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-617.
14. HJ GS, Julian PT, Higgins, Sally Green. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org; 2011.
15. Afifi AA, Elashoff RM, Lee JJ. Simultaneous non-parametric confidence intervals for survival probabilities from censored data. Stat Med. 1986;5: 653-662.
16. Choi MK, Hong JY, Chang W, et al. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Cancer Chemother Pharmacol. 2014;73:1217-1225.
17. Kinoshita T, Azuma K, Sasada T, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett. 2012;4:477-482.
18. Okuda K, Hirose T, Oki Y, et al. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer Res. 2012;32:5475-5480.
19. Shukuya T, Ishiwata T, Hara M, et al. Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res. 2010;30:4357-4361.
20. Watanabe N, Taniguchi H, Kondoh Y, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85:326-331.
21. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002;77:763-770.
22. Blaha H, Karg O, Cujnik F. Coincidence of pulmonary fibrosis and bronchial carcinoma (author's transl). MMW, Munchener Medizinische Wochenschrift. 1981;123:289-294.
23. Cohn JR. Interstitial lung disease and cancer chemotherapy. Ann Intern Med. 1979;90:856.
24. Ho JC, Lam WK, Ooi GC, et al. Lymphoepithelioma-like carcinoma of the lung in a patient with silicosis. Eur Respir J. 2003;22:383-386.
25. Kreuter M, Ehlers-Tenenbaum S, Schaaf M, et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 2015;31:266-274.
26. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested casecontrol study. Am J Respir Crit Care Med. 2008;177:1348-1357.
27. Minegishi Y, Takenaka K, Mizutani H, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med (Tokyo, Japan). 2009;48:665-672.
28. Ohno S, Oshikawa K, Kitamura S, et al. Clinico-pathological analysis of interstitial pneumonia associated with collagen vascular disease in patients with lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35:1324-1329.
29. Sagawa M, Takahashi S, Usuda K, et al. Interstitial pneumonia after CMC (CDDP, MMC, CPM) therapy. Gan no rinsho. Jpn J Cancer Clin. 1988;34:150-154.
30. Willson JK. Pulmonary toxicity of antineoplastic drugs. Cancer Treat Rep. 1978;62:2003-2008.
31. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251-6266.
32. Pilkington G, Boland A, Brown T, et al. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 2015;70:359-367.
33. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
34. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
35. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004;91(Suppl 2):S18-S23.
36. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132:1652-1658.
37. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132:214-220.
38. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27:143-150.
39. Barlesi F, Pujol JL. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer (Amsterdam, Netherlands). 2005;49:289-298.
40. Hotta K, Matsuo K, Ueoka H, et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol. 2004;15:1782-1789.